Stimvia develops a non-invasive neuromodulation platform for chronic conditions where dysfunctional neural control contributes to symptoms. The company’s lead product is positioned for clinical and home-based therapy, with an initial focus on urinary dysfunction.

The URIS system delivers electrical stimulation via dedicated electrodes, targeting peripheral nerves (including a peroneal nerve approach) to influence bladder-control circuits at peripheral, spinal, and supraspinal levels. The platform combines a nerve stimulator with software that supports parameter setting and therapy tracking, including a mobile application.

Primary use cases include overactive bladder and lower urinary tract symptoms such as urgency, frequency, nocturia, and incontinence. Stimvia also signals clinical exploration in movement-disorder symptoms (including Parkinson’s disease and essential tremor) as an extension of the same stimulation approach, while remaining centered on regulated clinical deployment.